Key Developments For Trubion Pharmaceuticals, Inc.
Trubion Pharmaceuticals, Inc. (TRBN.O) (Consolidated Issue listed on NASDAQ Global Market)
Trubion Pharmaceuticals, Inc. Announces Transition In Company Leadership
Trubion Pharmaceuticals, Inc. announced that Peter Thompson, President, Chief Executive Officer (CEO), Chairman of the Board of Directors and co-founder of the Company, has retired from the Company to pursue other interests. Steven Gillis, former Lead Director of the Company's Board of Directors, has been appointed Executive Chairman of the Board and Acting President. The Company will initiate shortly a formal search for a new Chief Executive Officer.
Trubion Pharmaceuticals, Inc. Announces Acceptance of Two Presentations On Its TRU-016 Product Candidate At 2009 ASH Annual Meeting
Trubion Pharmaceuticals, Inc. announced the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, Louisiana. The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating the effect of Trubion's Tru-ADhanCe technology in promoting enhanced natural killer cell mediated cytotoxicity against primary CLL cells. TRU-016 is Trubion's CD37-targeted therapy for the treatment of B-cell malignancies and is being developed in collaboration with Facet Biotech Corporation.
Trubion Pharmaceuticals, Inc. Reaffirms FY 2009 Revenue Guidance
Trubion Pharmaceuticals, Inc. reiterated its fiscal 2009 revenues of approximately $15 million to $20 million.
Trubion Pharmaceuticals, Inc. Announces Positive Data From Phase 2b Re-treatment Study of TRU-015
Trubion Pharmaceuticals, Inc. announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA. The Phase 2b trial is a double-blind, placebo-controlled, randomized study that is designed to evaluate the safety, tolerability, pharmacodynamics (PD), pharmacokinetics (PK) and clinical activity of repeat doses of TRU-015. Of the 276 original patients who began the study, 240 (204 of whom were rheumatoid-factor positive, or RF+) entered the first open-label re-treatment portion (R1) of the trial. Trubion announced the first course of re-treatment data from this study at the 2009 EULAR Annual Meeting in June 2009. A total of 226 patients from R1 were enrolled in the second re-treatment portion (R2) of the trial. At 24 weeks after the second re-treatment course, subjects in the group that had received 800 mg of TRU-015 in the initial treatment and re-treatments R1 and R2 achieved ACR 20, 50 and 70 response rates of 72%, 39% and 21%, respectively. Results were similar to the response rates achieved in R1 (70%, 40% and 23%, respectively).
Facet Biotech Corporation And Trubion Pharmaceuticals, Inc. Announce Worldwide Collaboration For Development And Commercialization of TRU-016
Facet Biotech Corporation and Trubion Pharmaceuticals, Inc. announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37 directed Small Modular ImmunoPharmaceutical (SMIP) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.
